Rakuten Medical, Inc.
Last verified 2026-05-08. JSON
| Total raised | $112.0M |
|---|---|
| Latest round | Funding round, $112.0M, 2025-07-11 |
| Founded | unknown |
| Headquarters | San Diego, CA |
| Industry | biotechnology |
| Stage | unknown |
| Website | rakutenmedical.com |
Rakuten Medical is a biopharmaceutical company developing Akalux, a photoimmunotherapy drug that kills cancer cells by activating a light-sensitive antibody conjugate injected into the tumor site. The approach destroys tumor cells while sparing surrounding healthy tissue, approved in Japan for head and neck cancer.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-07-11 | Funding round | $112.0M | undisclosed |
Detected tech stack
Cloudflare, WordPress, Max Mega Menu 3.9.2.1, Yoast SEO 27.5, reCAPTCHA, Google Analytics, Google Tag Manager, SiteOrigin Widgets Bundle 1.72.0, jQuery Migrate 3.4.1, DoubleClick Floodlight, Cloudflare Bot Management, CookieYes 3.4.2
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $112.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $112.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | rakutenmedical.com, read 2026-05-08 |
| Description | self-reported | rakutenmedical.com, read 2026-05-08 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $112.0M, 2025-07-11 → Funding round, $112.0M, 2025-07-11, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $112.0M, 2025-07-11 → Funding round, $112.0M, 2025-07-11 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes